Disaggregated Revenues (Tables)

6 Months Ended

Jun. 30, 2024

Disaggregation of Revenue [Abstract]

Disaggregation of Revenues

The following table summarizes the disaggregation of revenues by product (dollars in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	(unaudited)				(unaudited)
Net product sales
Qelbree	$	59,395	$	30,977	$	104,499	$	56,759
GOCOVRI	31,703		28,751		58,265		54,761
Oxtellar XR	29,516		23,800		56,459		52,715
APOKYN	17,295		17,605		33,944		34,814
Trokendi XR	17,086		19,319		33,075		54,109
Other(1)	7,543		7,884		14,757		15,753
Total net product sales	162,538		128,336		300,999		268,911
Royalty, licensing and other revenues	5,787		7,227		10,970		20,416
Total revenues	$	168,325	$	135,563	$	311,969	$	289,327

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.